This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/drugbank/drug/DB05868/identifier/drugbank/
n8http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB05868/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05868/identifier/wikipedia/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB05868/identifier/bindingdb/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05868/identifier/pubchem-compound/

Statements

Subject Item
n2:DB05868
rdf:type
n3:Drug
n3:description
The compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.
n3:generalReferences
# Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G: Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology. 2007 Oct;133(4):1144-55. Epub 2007 Jul 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17919490
n3:group
investigational
n3:indication
Investigated for use/treatment in hepatitis (viral, C).
owl:sameAs
n8:DB05868
dcterms:title
BILN 2061
adms:identifier
n6:50142916 n10:9853710 n11:Protease_inhibitor_%2528pharmacology%2529 n12:8029420 n13:DB05868
n3:mechanismOfAction
A distinguishing feature of the BILN 2061 inhibitor series is the presence of C-terminal carboxylic acid functionality. This provides exquisite selectivity with respect to other proteases, a property not easily attained with more conventional classes of covalent, reversible serine protease inhibitors. BILN 2061 blocks NS3 protease-dependent polyprotein processing in HCV replicon-containing cells. It is orally bioavailable in various animal species.
n3:IUPAC-Name
n4:271B4816-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B481C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B481B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4818-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4819-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B481A-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4814-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4815-363D-11E5-9242-09173F13E4C5 n4:271B4812-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4813-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4822-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4823-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B481D-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B481E-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4820-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B481F-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4821-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4828-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B482A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B482B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4827-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4826-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4829-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4817-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4824-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4825-363D-11E5-9242-09173F13E4C5